Stock Movers: Chevron, Delta, Him & Hers (Podcast)

30%: Ultrapar is in advanced talks to sell a 30% stake in Ipiranga to Chevron with price agreed and governance discussions underway, prompting Chevron shares to rise. Airlines, led by Delta, fell after Monday’s spike in oil that pressured travel, auto, retail and restaurant stocks. Hims (HIMS) surged after Novo Nordisk agreed to sell its weight‑loss drugs on the Hims platform and a partnership announcement is expected imminently.

Analysis

Major integrated energy players are being re-valued by the market when regional downstream assets trade or are repriced; that process typically lifts headline multiples for the parent because minority‑stake deals crystallize a local retail EBITDA multiple that investors then apply to otherwise opaque pipelines of non‑core assets. Expect the largest re-rating pressure to occur within the next 3–6 months as governance terms (board seats, earnouts, pricing collars) become public — these details materially change free‑cash‑flow transfer mechanics and the speed at which cash hits a parent balance sheet.

Airlines are highly sensitive to short, sharp oil moves because ticket pricing lags costs and hedges cover only a portion of fuel exposure; a sustained oil shock compresses CASM and forces capacity discipline or fare hikes that take quarters to flow through. Positioning should distinguish a 1–3 month liquidity pain (flow‑driven selling) from a 6–12 month structural revenue hit — the latter requires oil to remain elevated and ASK discipline to fail concurrently.

For consumer health/telemedicine platforms, a distribution agreement for high‑value GLP‑1 therapeutics is more than incremental sales — it can convert a subscription user base into a high‑margin recurring pharmacy revenue stream and create cross‑sell synergies that lift LTV by multiples. Countervailing risks include margin sharing with manufacturers, stricter dispensing scrutiny from payors/regulators, and potential churn if side‑effect management is inadequate; these are 3–12 month execution risks that will show up in conversion and adherence metrics.

Watch the interplay between asset‑sale financing and share capital actions: divestment proceeds often trigger buybacks or accelerate capex in competing businesses, which can amplify short‑term EPS beats but introduce longer‑term reinvestment trade‑offs. Governance concessions in minority deals frequently embed ratchets that can dilute upside for shareholders if contingent earnouts aren't correctly modeled into present value.

Key Decisions for Investors

• Long CVX (3–6 month horizon): allocate 2–4% net exposure to stock or buy 3‑month calls (~ATM) if implied vol is < historical realized; target +12–18% on successful monetization re‑rating, stop at -6% if transaction talks falter or guidance disappoints.
• Pair trade — short DAL vs long XLE (1–3 month horizon): size net neutral (equal $) and implement via buying 3‑month DAL put spread (defined risk) and buying XLE outright. Rationale: transitory oil shock should hurt airline cashflows faster than it benefits integrated energy; target asymmetric 2:1 upside, maximum premium risk on the put spread.
• Long HIMS (6 month horizon) via call options or small equity tranche: allocate up to 2% notional in 6‑month calls to capture commercial rollout upside; expected 40–80% upside if conversion/adherence metrics prove favorable, with a hard stop to cut losses at -30% on position value given regulatory/execution binary risk.
• Event monitor & hedge: if oil sustains >$90/bbl for >30 days, add delta hedges to airline shorts and consider trimming energy exposure above realized gains; conversely, if governance terms of major minority asset deals include onerous earnouts, trim CVX exposure immediately (time horizon: immediate to 1 month).